PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer

Background: Immune checkpoint inhibitors (ICIs) have become the standard treatment for advanced non-small cell lung cancer (NSCLC). ICIs can provide durable responses and prolong survival for some patients. With the increasing routine of next-generation sequencing (NGS) in clinical practice, it is e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Zhixuan, Wang, Li, Leng, Chaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497019/
https://www.ncbi.nlm.nih.gov/pubmed/37602864
http://dx.doi.org/10.18632/aging.204964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497019/
https://www.ncbi.nlm.nih.gov/pubmed/37602864
http://dx.doi.org/10.18632/aging.204964

Ejemplares similares